Shanghai, China and New Jersey, U.S., January 6, 2023—Laekna Therapeutics will be attending the Annual J.P. Morgan Healthcare Conference which will take place on January 9-12 in San Francisco, US. Our CEO, Chris Lu along with our VP, Head of Corporate and Business Development, Guy Rosenthal and Director of Corporate and Business Development, Padmini Jayaraman, PhD, will attend the conference and are excited to share Laekna’s strong clinical programs as well as innovative and diverse pipeline with potential partners.
The J.P. Morgan Annual Healthcare Conference is the largest and most informative healthcare investment symposium in the industry which connects global industry leaders, emerging fast-growth companies, innovative technology creators and members of the investment community.
Founded in 2016, Laekna is a clinical-stage biotechnology company, dedicated to bringing ground-breaking therapies to cancer and liver fibrosis patients worldwide.
Laekna has two potential core products: LAE002 is an investigational highly selective adenosine triphosphate (ATP) competitive AKT inhibitor for the treatment of ovarian cancer, prostate cancer, breast cancer and PD-1/PD-L1 drug-resistant solid tumors. The other core product LAE001 is an investigational androgen synthesis inhibitor that simultaneously inhibits both CYP17A1 and CYP11B2 for the treatment of prostate cancer.
Laekna’s robust infrastructure has already enabled the rapid development of 14 innovative product candidates, including one pivotal clinical trial and another five clinical trials for its potential core products. Among these six clinical trials, three multi-regional clinical trials (MRCTs) are designed to address urgent yet unmet global medical needs in the standard of care (SOC)-resistant cancers.
Laekna’s internal drug discovery primarily focuses on coordinating the human immune system to treat cancer and liver fibrosis.
For more information, please visit: https://www.laekna.com/
Corporate and Business Development
Follow us on Linkedin